Disease · MONDO_0005314
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alemtuzumab Treatment CAMMS323 Extension vs Alemtuzumab Treatment CAMMS324 Extension: Number of Participants With Sustained Accumulation of Disability (SAD) | 79 of 376 | 118 of 426 | 802 | NCT00930553 | Trial comparisons |
| Ocrelizumab vs Ocrelizumab Safety Follow-up: deaths from any cause | 1 of 680 | 0 of 64 | 744 | NCT02861014 | Trial comparisons |
| Ocrelizumab vs Ocrelizumab Safety Follow-up: serious adverse events | 49 of 680 | 6 of 64 | 744 | NCT02861014 | Trial comparisons |
| Alemtuzumab Treatment CAMMS323 Extension vs Alemtuzumab Treatment CAMMS324 Extension: Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS at Year 6 | 74 of 235 | 130 of 321 | 556 | NCT00930553 | Trial comparisons |
| Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: Number of Participants With At Least One Concomitant Medication | 98 of 103 | 73 of 85 | 188 | NCT03933202 | Trial comparisons |
| Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: deaths from any cause | 2 of 103 | 0 of 85 | 188 | NCT03933202 | Trial comparisons |
| Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: serious adverse events | 10 of 103 | 14 of 85 | 188 | NCT03933202 | Trial comparisons |
| Ofatumumab-Treated vs Healthy Control: deaths from any cause | 0 of 119 | 0 of 61 | 180 | NCT05084638 | Trial comparisons |
| Ofatumumab-Treated vs Healthy Control: serious adverse events | 8 of 119 | 3 of 61 | 180 | NCT05084638 | Trial comparisons |
IFNB-1a/Alemtuzumab Switch CAMMS323/03409 (Post Alemtuzumab) vs IFNB-1a/Alemtuzumab Switch CAMMS324/03409 (Post Alemtuzumab): Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS (After Alemtuzumab Treatment) at Year 2 of the Extension Study | 11 of 65 | 14 of 102 | 167 | NCT00930553 | Trial comparisons |
D-aspartate + IFN Beta-1a + Methylprednisolone vs Placebo + IFN Beta-1a + Methylprednisolone: Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 | 1 of 5 | 0 of 2 | 7 | NCT03387046 | Trial comparisons |
| D-aspartate + IFN Beta-1a + Methylprednisolone vs Placebo + IFN Beta-1a + Methylprednisolone: deaths from any cause | 0 of 5 | 0 of 2 | 7 | NCT03387046 | Trial comparisons |
| D-aspartate + IFN Beta-1a + Methylprednisolone vs Placebo + IFN Beta-1a + Methylprednisolone: serious adverse events | 0 of 5 | 0 of 2 | 7 | NCT03387046 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005314/comparisons